Skip to main content
. 2016 May 29;7(28):43062–43075. doi: 10.18632/oncotarget.9657

Figure 5. BO-1055 inhibits Ewing sarcoma tumor growth in NSG mice and and causes complete regression of rhabdoid tumor growth in nude mice.

Figure 5

A. NSG mice (n = 5 per group) bearing A673 xenografts of approximately 100mm3 size were given 5 doses of BO-1055 at 10mg/kg, 20mg/kg and 30mg/kg doses by tain vein injection. Tumor volume was measured twice a week and plotted. B. Weights of NSG mice treated at different doses of BO-1055. C. Nude mice (n = 5 per group) bearing A204 xenografts were treated with BO-1055 at a dose of 30mg/kg for doses by tail vein inj. Complete regression of tumors were noted in the treated group. D. Xenografts in NSG mice were developed from a patient with relapsed Ewing sarcoma. When the tumors reached 100mm2, we randomized mice in to control and drug treatment groups (n = 5 per group). Drug treatment group received MTD dose of cyclophosphamide 70mg/kg i.p. q2d for 3 doses (shown by shorter arrows). Tumor growth was not inhibited in the cyclophosphamide treated mice. When the tumors reached above 500mm3, we started treatment with BO-1055 at a dose of 30mg/kg i.v. q2d for 4 doses (shown by longer arrows).